Skip to main content

Landon Capital

This doesn’t look right, FDA places Bright Minds Biosciences BMB-101 trial on partial hold

Written By Keith Pinder

Bright Minds Biosciences Inc. (DRUG) announced that the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s investigational new drug application for BMB-101 in Developmental and Epileptic Encephalopathies, following an FDA review.

The hold affects a planned Phase 2 randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of ascending doses of BMB-101 for treating seizures associated with DEEs. The company stated the hold does not affect its other ongoing clinical trials.

The FDA cited toxicity identified in mice and insufficient pharmacokinetic and juvenile toxicity data to support the proposed pediatric enrollment as the primary reasons for the hold. Bright Minds stated its belief, based on toxicity reports and independent expert opinions, that the adverse mouse findings were incidental and not drug-related. The company noted these are its own beliefs and should not be interpreted as FDA findings or as resolving the FDA’s stated concerns.

The company is awaiting the FDA’s full Partial Clinical Hold Letter, which the agency said it would deliver within 30 days. The letter is expected to include additional details, non-hold recommendations, and study-design recommendations.

About Landon Capital
Landon Capital Inc. is a media company that wholly owns subsidiaries Landon Capital Management LLC and Landon Capital News. Landon Capital News distributes economic, and political news in over 176 countries. Landon Capital News provides an in depth and simplistic look at financial, economic, and political news, as it is happening. We also provide our viewers with in-depth analysis on various companies and political news that directly correlate to economics. We bridge the gap of information between the investor and the markets, sectors and industries that they invest. For more information, please contact us at info@landoncapital.net or 404-995-6671 or visit https://landoncapital.net.


Safe Harbor Statement
This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Landon Capital received no direct compensation related to this release. This release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Actual results may differ materially from those stated or implied in.